L-Arginine Hydrochloride pharmaceutical-grade API, product code LAH-PG-10 for oral solid dosage and LAH-PG-10-I for injectable formulations, is the monohydrochloride salt of (S)-2-amino-5-guanidinopentanoic acid, CAS 1119-34-2, molecular formula C₆H₁₄N₄O₂·HCl, and molecular weight 210.66 g/mol. The material is released as a white or almost white crystalline powder and is manufactured under a quality system aligned with ICH Q7 and applicable national GMP regulations. The hydrochloride counterion supplies 16.8% w/w chloride and reduces the free-base amine concentration; a 10% w/v aqueous solution has a specification pH range of 5.0–6.5 when measured according to Ph.Eur. 2.2.3.

The product is intended as an API for tablets, capsules, granules, oral solutions, and injectable dosage forms. The two product codes differ in the extent of microbial and endotoxin control: LAH-PG-10 is released against non-sterile oral limits, while LAH-PG-10-I is released against reduced bioburden and bacterial endotoxin limits. Both codes are supplied as milled or sieved powders with controlled particle-size distribution, and both are packed in double polyethylene bags inside sealed aluminium-laminated drums with desiccant. The assigned retest period for unopened material is 24 months when stored at 20–25 °C and <40% relative humidity.

Release control includes assay on the dried basis from 98.5% to 101.0% by potentiometric titration, specific rotation from +21.5° to +23.5° measured polarimetrically according to Ph.Eur. 2.2.7, loss on drying not more than 0.5% after 105 °C to constant weight, sulfated ash not more than 0.1%, and chloride content 16.7–17.4% on the dried basis. Residual solvents are controlled according to USP <467>, elemental impurities by ICH Q3D, and microbial quality by USP <61> and USP <62>.

How Does the Monohydrochloride Counterion Alter Formulation Behaviour?

The hydrochloride salt is selected over the free base when aqueous solubility and acidified solution pH are required in oral or injectable manufacturing. The chloride counterion has a mass fraction of 16.8%, so the theoretical L-arginine content is 82.7% w/w; batch calculation for tablet and capsule label claim must correct for this mass balance. The compendial solubility classification of the hydrochloride is very soluble in water; the resulting solution pH in the range 5.0–6.5 reduces the alkaline excursion observed with the free base and is compatible with standard stainless-steel transfer lines.

In direct compression, the material is specified with a laser-diffraction particle-size distribution of D10 ≥ 40 µm, D50 100–180 µm, and D90 ≤ 300 µm when tested according to ISO 13320. Bulk density is controlled at 0.45–0.60 g/mL and tapped density at 0.55–0.75 g/mL by USP <616>. These limits are tightened compared with a generic milled ingredient because dosator-type capsule filling machines exhibit fill-weight drift when bulk density shifts by more than 0.05 g/mL across batches. On a 27-station rotary tablet press with forced feeder, powder bed height below 10 mm and feed frame speed above 40 rpm have been associated with weight variation; a lubricated blend containing 0.5% w/w sodium stearyl fumarate and 3 min mixing time reduced ejection force below 1.2 kN in single-punch trials.

For wet granulation, the high aqueous solubility of the hydrochloride limits the water quantity that can be added before the mass becomes adhesive. In a 10 L high-shear granulator with chopper speed 1500 rpm, water addition of 8–12% w/w produced granules suitable for tablet compression; water addition above 15% w/w formed a deformable mass that adhered to the bowl wall and reduced subsequent tablet hardness uniformity. Drying in a fluid-bed dryer at inlet air temperature 60–65 °C to a granulate loss on drying of 1.0–1.5% is specified; residual moisture outside this range increases either punch sticking or tablet friability. Disintegration testing is performed according to USP <701> at 37 °C using water.

If Low Endotoxin Load Is Required for Injectable Formulations

For parenteral dosage forms, LAH-PG-10-I is controlled as a low-burden non-sterile API intended for downstream sterile filtration or aseptic processing. Bacterial endotoxins are determined by kinetic chromogenic LAL according to Ph.Eur. 2.6.14 or USP <85>; the acceptance limit is set at 0.25 EU/mg unless the maximum daily dose calculation requires a stricter value. Bioburden is limited to total aerobic microbial count ≤ 10² CFU/g and total yeast and mold count ≤ 10¹ CFU/g according to USP <61>. The product is not supplied as sterile; terminal sterilisation or aseptic filtration of the finished solution is required to make a sterile claim. A 100 mg/mL aqueous solution is normally filtered through a 0.22 µm polyethersulfone membrane before filling; the solution pH is maintained at 5.0–6.5 to avoid precipitation at higher pH and to limit chloride-associated corrosion of stainless-steel filling line equipment.

Sub-visible particulate matter of the finished injection is tested according to USP <788> after the final filter; the API itself is not in solution and is not tested by that method. The injectable grade includes reduced aluminium and heavy-metals limits in the risk assessment under ICH Q3D, and residual solvents are controlled to parenteral acceptance values. Published data for the specific endotoxin clearance efficiency of terminal filtration of this API is limited; filter validation should be performed with the target solution because the low solution pH and chloride concentration may influence membrane binding.

Injectable solutions should not be compounded with strong oxidising agents or nitrite-containing formulations unless the finished product is assessed for nitrosamine formation under ICH M7. The API is not compatible with alkaline admixtures intended for long storage because the pH shift may reduce solubility and produce free-base precipitation. Forced-degradation studies on the finished formulation are recommended under ICH Q1A(R2) to establish the degradation profile of the hydrochloride counterion in the chosen primary package.

Granulation and drying of LAH-PG-10 are governed by the narrow particle-size and moisture limits rather than by a single granulation method. Roller compaction has been used as an alternative to wet granulation for formulations that are sensitive to aqueous processing; typical roll pressure is 4–8 kN/cm with a roll gap of 1.0–2.0 mm, followed by milling through a 0.8 mm screen. The resulting granules have a bulk density higher than the milled powder, and the flow function coefficient measured by ring shear tester increases from 3.5 to 6.0, moving the material from the cohesive to the easy-flow region according to Jenike classification. Published data for this specific LAH-PG-10 morphology is limited, so the roll compaction parameters are provided as process development boundaries rather than validated release conditions.

Encapsulation of the dry-granulated material on a dosator machine requires tapped density consistency within 0.05 g/mL and mass flow rate not less than 8 g/s through a 10 mm funnel orifice, which is tested by USP <1174> powder flow methods. Process rooms are maintained at 20–25 °C and <40% RH; uncoated powder exposed to relative humidity above 60% shows reduced flow and increased adhesion to contact surfaces. Tablet and capsule formulations should use an internal disintegrant such as croscarmellose sodium at 2–4% w/w and a water-soluble filler because the hydrochloride itself dissolves rapidly and may create channels during disintegration; testing by USP <701> is used to confirm that the chosen lubricant level does not delay release.

Pharmacopoeial Specification Crosswalk for LAH-PG-10

The pharmacopoeial crosswalk below summarises the release specification for the oral solid dosage grade and the injectable grade; the table is a routine control set, not a complete certificate of analysis. Methods listed as compendial are run in compliance with the cited general chapters, while in-house methods are validated according to ICH Q2(R1).

Because the compendial methods for related substances may not be fully harmonised across Ph.Eur., USP, and JP, the product specification sheet states the compendial axis used for release. Chromatographic related-substances testing uses a validated high-performance liquid chromatography method with charged aerosol detection because the amino acid lacks a strong UV chromophore; the method is validated for specificity, linearity, accuracy, and precision according to ICH Q2(R1). In the release method, any unspecified impurity is limited to 0.1% and total impurities to 1.0%. For oral grade, Class 3 residual solvents are limited to 0.5% w/w under Ph.Eur. 2.4.24; for injectable grade, the same solvents are controlled to 0.1% w/w on the certificate of analysis to reduce total solvent load before terminal filtration.

Chloride Content and Compaction Behaviour Distinguish the Hydrochloride Salt

Compared with L-arginine base, the hydrochloride salt replaces the free amine group with a chloride salt, altering the solution pH, chloride exposure, and mass-balance correction. The table below shows common L-arginine entities used in pharmaceutical and nutritional formulations. The hydrochloride is distinguished by the highest chloride content and the lowest alkaline excursion, making it useful for injectable and acidified oral formulations; the base and other salts are used when chloride load or counterion-specific effects are not acceptable.

In tablet and capsule processing, the hydrochloride salt may be incorporated at up to 70% w/w in a direct-compression formula with microcrystalline cellulose and croscarmellose sodium. Ejection force on a single-punch press was measured below 1.2 kN with 0.5% w/w magnesium stearate and a mixing time of 3 min; mixing beyond 10 min delayed disintegration because of lubricant coating. These process values are specific to the LAH-PG-10 particle-size range and should be re-established if a different particle morphology or another salt form is substituted.